title: HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity.
abstract: The mechanisms by which tumour cells escape recognition by the immune system or subvert antitumour effector responses remain poorly understood. In the course of investigating the potential of costimulatory signals in anticancer immunotherapy strategies, we have observed that HeLa cells (a human cervical carcinoma cell line) cocultured with peripheral blood lymphocytes (PBL) acquire the capacity to inhibit PBL proliferation in response to interleukin-2 (IL-2). This immuno-inhibitory phenotype was further shown to result from induction of the tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO), by interferon-gamma (IFN-gamma) secreted from cocultured allo-reactive PBL. This enzyme has recently been shown to be a critically important modulator of immunological responses, most notably through the capacity to protect allogeneic concepti from alloreactive maternal lymphocytes. While the cytostatic consequences of IDO activity in tumour cells has received attention, the data presented in this report support the hypothesis that IDO activity may also act to impair antitumour immune responses.
authors: Gene Therapy Research Unit of The Children's Medical Research Institute and The Children's Hospital at Westmead, Wentworthville NSW 2145, Westmead, Australia.
authors: Grant J
authors: GJ
authors: Logan
authors: Christine M F
authors: CM
authors: Smyth
authors: John W
authors: JW
authors: Earl
authors: Irina
authors: I
authors: Zaikina
authors: Peter B
authors: PB
authors: Rowe
authors: Jason A
authors: JA
authors: Smythe
authors: Ian E
authors: IE
authors: Alexander
mesh_terms: D018122:B7-1 Antigen / Q000276:immunology; D002455:Cell Division; D018920:Coculture Techniques; D024881:Drug Resistance, Bacterial / Q000235:genetics; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006367:HeLa Cells / Q000276:immunology*; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D008214:Lymphocytes / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D014364:Tryptophan / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D014366:Tryptophan Oxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D018122:B7-1 Antigen; D004791:Enzyme Inhibitors; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007376:Interleukin-2; C028129:tryptophan methyl ester; D007371:Interferon-gamma; D014364:Tryptophan; D014366:Tryptophan Oxygenase